Carnitine Supplementation in Pediatric Hemodialysis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-01

Study Completion Date

2024-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is:

1. To determine the prevalence of carnitine deficiency among pediatric patients on hemodialysis.
2. To evaluate the efficiency of carnitine supplementation in children on regular hemodialysis with carnitine deficiency in the treatment of renal anemia, cardiac dysfunction, dyslipidemia, intradialytic muscle cramps and hypotension and their quality of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Alpha Lipoic Acid in Pediatrics on Hemodialysis

NCT06286098

Hemodialysis Complication Pediatric Kidney Disease Cardiovascular Complication

ENROLLING_BY_INVITATION PHASE3

Effect of Protein Restriction Plus EAA/KA Supplementation on GFR Decline in CKD

NCT05952544

Chronic Kidney Diseases

COMPLETED

Cholecalciferol Supplementation in Hemodialysis Patients

NCT05922696

Anemia Hemodialysis Complication Vitamin D Deficiency

COMPLETED PHASE2/PHASE3

Efficacy and Safety of Coenzyme Q10 in Pediatric Hemodialysis Patients

NCT05170893

Hemodialysis

COMPLETED NA

Effect of Vitamin K 2 on Vascular Calcification in Hemodialysis Patients

NCT04145492

End Stage Renal Disease

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients on hemodialysis (HD) often have carnitine deficiency due to multiple factors; dietary intake of carnitine is decreased due to falls in appetite, total energy levels, and protein intake. In addition, accumulating evidence has linked inflammation to malnutrition, and chronic inflammation might also interrupt carnitine transfer in the intestine. Carnitine biosynthesis can also fall in patients on dialysis due to reduced biosynthesis in the kidney and limited compensation by the liver. Furthermore, because of the low molecular weight of carnitine and its high hydrophilicity and absence of protein binding, carnitine is significantly removed by the dialyzer. As in the healthy population, carnitine deficiency in patients receiving maintenance dialysis is most commonly defined as a serum free carnitine level less than 20 μmol/L .

Intravenous levocarnitine is commonly used to treat patients receiving maintenance hemodialysis who are diagnosed with carnitine deficiency since it has 100%bioavailability and does not break down into toxic metabolites. A common dose used for carnitine supplementation is 10-20 mg/kg administered after each hemodialysis session, which produces the supraphysiologic serum levels of carnitine that are required to adequately drive carnitine from the serum into skeletal muscles.

There are four principal indications for levocarnitine treatment in dialysis patients with carnitine deficiency according to the American National Kidney Foundation: (1) erythropoiesis stimulating agents resistant anemia that has not responded to the standard erythropoiesis stimulating agent dosage; (2) recurrent symptomatic hypotension during hemodialysis;(3) symptomatic cardiomyopathy or confirmed cardiomyopathy with reduced left ventricular ejection fraction and(4) fatigability and muscle weakness that undermine the quality of life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carnitine Deficiency Due to Hemodialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

L-Carnitine Group

Enrolled patients in this group who are on regular hemodialysis fulfilling our study's inclusion criteria with secondary carnitine deficiency(based on clinical manifestations and decreased serum level of L-carnitine ;serum free carnitine level less than 20 μmol/L) will receive intravenous L-carnitine (20 mg/kg dry body weight) after each dialysis session three times weekly for 6 months.

Group Type EXPERIMENTAL

L-carnitine

Intervention Type DRUG

L-carnitine supplementation

Placebo Group

enrolled patients in this group who will receive 5 ml intravenous isotonic saline after each dialysis session three times weekly for 6 months.

Group Type PLACEBO_COMPARATOR

isotonic saline

Intervention Type OTHER

Intravenous 5 ml of isotonic saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L-carnitine

L-carnitine supplementation

Intervention Type DRUG

isotonic saline

Intravenous 5 ml of isotonic saline

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients on regular hemodialysis for more than three months with L-carnitine deficiency.
* Anemia (hemoglobin \[Hb\] \< 11 g/dl; hematocrit \[Hct\] \< 30%) resistant to erythropoietin defined as Anemia that require recombinant human erythropoietin (rHuEPO) doses \>300 units/kg/week intravenously in spite of adequate iron stores (transferrin saturation \>20%, ferritin \>100 ng/mL), and without any other identifiable cause of anemia.
* Recurrent intradialytic complications (cramping, muscular pain, hypotension)
* Cardiomyopathy with reduced left ventricular ejection fraction.
* Sex: both males and females.
* Age: 16 years old or less.

Exclusion Criteria

* Patients known to be allergic to L-carnitine.
* Patients with inborn error of metabolism.
* Patients on lipid lowering therapy.
* Patients with Diabetes mellitus.
* Patients with Associated congenital heart disease.
* Patients with Thyroid disorder, or malignancy.
* Patients received L-carnitine within the past 6 months.
* Patients received Blood transfusion 4 weeks prior to study.

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No